FDA approved Afinitor (everolimus), sponsored by Novartis, for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors of gastrointestinal or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival in a multicenter, randomized, placebo-controlled trial of everolimus 10 mg orally once daily...
In this episode of In the Headlines, Jacquelyn Cobb, associate editor of the The Cancer Letter, and Claire Marie Porter, reporter, discuss Claire’s interview with an NCI employee who was fired just days after returning from parental leave.
